Xian-Ming Zeng Ph.D. has over 25 years of experience in leading multidisciplinary teams for the development and commercialization of generic and branded inhalation products for advanced markets. He has held global R&D leadership roles at Ivax, Teva and Lupin in the UK and US, and led the successful development of multiple DPI products (SABA, LAMA, ICS, ICS-LABA combinations), MDI products (SABA, ICS, ICS-LABA combinations), Inhalation Solutions and Suspensions (ICS, antibiotics, LABA) and an ICS HFA nasal spray.
Xian-Ming Zeng Ph.D. is also an academician, having served King’s College London as a Maplethorpe Postdoctoral Fellow and Visiting Professor, followed by being appointed as Professor of Pharmaceutics and Director of Research at Medway School of Pharmacy, University of Kent. His academic research has led to the publication of a text book, a book chapter and over 50 peer-reviewed research papers.
Xian-Ming Zeng Ph.D. is a regular speaker at many national and international conferences on inhalation product development and regulation. Apart from serving European Pharmaceutical Aerosol Group, he was also a board member of International Pharmaceutical Aerosol Consortium on Regulation and Science. He currently serves as a scientific advisor for Spectrum Dynamic Research in the US.